M A Hoffman1, J A Blessing, E R Nuñez. 1. Division of Hematology-Oncology, Long Island Jewish Medical Center, Campus of the Albert Einstein College of Medicine, New Hyde Park, New York 11040, USA. hoffman@lij.edu
Abstract
OBJECTIVES: To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients. METHODS: Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations. CONCLUSIONS: CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested. Copyright 2001 Academic Press.
OBJECTIVES: To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients. METHODS:Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations. CONCLUSIONS:CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested. Copyright 2001 Academic Press.
Authors: Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh Journal: Gynecol Oncol Date: 2011-07-12 Impact factor: 5.482
Authors: Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482